The company has signed agreements with MilliporeSigma to scale manufacturing and with Hamilton Company to market a turnkey solution to help CLIA laboratories rapidly add testing capacity
Heparan sulfate is increasingly recognized as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the current COVID-19 coronavirus pandemic